Latest News
-
Gold Prices India: 10 Grams Of 22K Yellow Metal Jumps After Falling By Rs 2000 -
New Safety Check System for Cooking Gas Connections Rolled Out Amidst Delivery Boy Grievances; Reports -
Okay Play India Posts 12.79% Revenue Growth In Q4 After 1:10 Stock Split Approval -
Highest Rs 70/Sh Dividend; Tata's IT Stock Falls After Q4; Rs 5,400/TP By Kotak, Brokerages Give Underweight -
Tesla Layoffs: CEO Elon Musk Fires Entire 4-Month Old US 'Growth Team'; Q1 Profit Slumps -
Axis Bank Q4 Results Preview: Profitability Likely To Drop Led By Higher Opex; Asset Quality May Remain Stable -
HUL Q4 Results Preview: Price Cuts Likely To Impact Topline Growth, Shares Gain 1.88% In 1-Week -
1:2 Split Soon: Tata's 79-Year-Old Auto Giant Rises 3,013% Before Splitting; Target Prices Rs 1,300-1,500 -
Trade Setup: Mixed Results From HDFC Bank, RIL Stall Nifty Momentum; Global Economic Data In Focus -
Rs 5/Share Dividend: Record Date On 13th June; Buy The Auto Stock?
Pfizer Jumps 8.5% As Parent Firm's Coronavirus Vaccine Shows Potential In Human Trials
Shares of Pfizer Limited rose as much as 8.5 percent to Rs 4,313.40 on BSE on Thursday after an early trial of the experimental coronavirus vaccine from the company's American parent Pfizer Inc and BioNtech SE showed it's safe and prompted patients to produce antibodies against the virus.
With over 10.5 million confirmed COVID-19 infections across the world, USA's Pfizer and Germany's BioNTech and other biopharmaceutical outfits and academic groups are in a race to come up with a safe and effective vaccine against the virus.
The messenger RNA product was tested on 45 healthy adults divided into several groups. The group that got two injections with two different doses of the experimental vaccine produced the highest level of antibodies.
On Wednesday, Pfizer Inc's shares gained as much as 5.6 percent in New York, while BioNtech shares jumped by as much as 19 percent in Germany. The companies said that the study of Pfizer's and BioNtech's vaccine candidate, called BNT162b1, is undergoing scientific peer review.
They are evaluating at least four experimental vaccines at various doses and will be picking the most promising one for the next stage of tests, which could start as early as this month and involve as many as 30,000 patients.
If the vaccine is successful, the companies expect to manufacture up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by the end of 2021.
